ストックスクリーナーアプリを入手
0.4981
4.12%
-0.0218
前日終値:
$0.5199
開ける：
$0.511
24時間の取引高:
602.76K
Relative Volume:
0.29
時価総額：
$93.96M
収益：
-
当期純損益:
$-32.54M
株価収益率:
-2.4905
EPS:
-0.2
ネットキャッシュフロー:
$-29.06M
1週間 パフォーマンス:
-5.23%
1か月 パフォーマンス:
-17.34%
6か月 パフォーマンス:
-32.31%
1年 パフォーマンス:
-34.33%
1日の値動き範囲:
$0.494
$0.528
1週間の範囲:
$0.48
$0.55
52週間の値動き範囲:
$0.48
$1.07
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
名前
Citius Pharmaceuticals Inc
セクター
電話
(908) 967-6676
住所
11 COMMERCE DRIVE, CRANFORD, NJ
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-11-30 | 開始されました | Maxim Group | Buy |
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News
Citius Pharmaceuticals defers FDA milestone payment - Investing.com
Citius Pharmaceuticals defers FDA milestone payment By Investing.com - Investing.com UK
Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Financial Metrics Check: Citius Pharmaceuticals Inc (CTXR)’s Ratios for Trailing Twelve Months - The Dwinnex
Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com
Citius Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com Canada
There is no way Citius Pharmaceuticals Inc (CTXR) can keep these numbers up - SETE News
Insider’s View: Deciphering Citius Pharmaceuticals Inc (CTXR)’s Financial Health Through Ratios - The Dwinnex
Can you still get a good price for Citius Pharmaceuticals Inc (CTXR) Shares at this point? - US Post News
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - The Malaysian Reserve
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Malaysian Reserve
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - PR Newswire
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
You might want to take a look at Citius Pharmaceuticals Inc (CTXR) now - SETE News
Market Momentum Report: Citius Pharmaceuticals Inc (CTXR)’s Positive Close at 0.57 - The Dwinnex
Citius Pharmaceuticals Inc (CTXR) requires closer examination - US Post News
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Drop in Short Interest - MarketBeat
Arkadios Wealth Advisors Has $88,000 Holdings in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com India
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com Canada
In the Green: Citius Pharmaceuticals Inc (CTXR) Closes at 0.59, Up/Down -12.96 from Previous Day - The Dwinnex
It makes sense and dollars to buy Citius Pharmaceuticals Inc (CTXR) stock - SETE News
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com UK
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Are Citius Pharmaceuticals Inc (CTXR) shares a good deal now? - US Post News
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks
CTXRW (Citius Pharmaceuticals) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia
Vanguard Group Inc. Has $6.29 Million Stake in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Oncology Inc. completes strategic acquisition - Investing.com
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Canada
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com UK
CTXRW (Citius Pharmaceuticals) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com
Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ
Citius Pharmaceuticals (NASDAQ:CTXR) Releases Quarterly Earnings Results - MarketBeat
Citius merges oncology subsidiary with TenX Keane - Yahoo Finance
Citius merges oncology subsidiary with TenX Keane - Pharmaceutical Technology
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - The Malaysian Reserve
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - StockTitan
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024 - Marketscreener.com
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - StockTitan
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - BioSpace
Citius Pharmaceuticals Inc (CTXR) 財務データ
収益
当期純利益
現金流量
EPS
1.25%
1.94%
大文字化:
|
ボリューム (24 時間):